New drug cocktail aims to wipe out breast cancer before surgery
NCT ID NCT05558722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding an oral targeted drug called anlotinib to standard chemotherapy can better clear cancer from the breast and lymph nodes before surgery in people with early-stage HER2-negative breast cancer. The study enrolled 31 high-risk patients. The main goal is to see how many achieve a complete response, meaning no cancer remains in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anlotinib (a targeted drug that blocks blood vessel growth) plus chemotherapy (albumin-bound paclitaxel, pirarubicin, cyclophosphamide)
What this could lead to
If successful, this combination could increase the chance of eliminating all cancer before surgery, potentially improving long-term outcomes for high-risk HER2-negative breast cancer patients.
What could go wrong
This is a small, early-phase study with only 31 participants and no comparison group. The added drug may cause more side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE II are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xijing Hospital Affiliated to Air Force Military Medical University
Xi'an, Shannxi Province, 710032, China